A phase 2 multinational global study evaluated the JAK1 selective inhibitor golidocitinib in r/r PTCL patients; in the 3 NKTCL patients, ORR was reported in 2 patients [89]. The gene discussed is JAK1; the disease is extranodal nasal NK/T cell lymphoma.